Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode pages of FDA jargon and clinical-trial tables in CeriBell’s disclosures? Medical-device filings are notoriously dense, and CeriBell’s focus on AI-driven EEG technology only adds layers of regulatory nuance. Whether you’re hunting for cybersecurity risks tied to VA deployments or details on subscription revenue, finding answers quickly can feel impossible.
Our platform fixes that. Stock Titan’s AI reads every CeriBell annual report 10-K simplified, flags key FDA 510(k) milestones in each CeriBell quarterly earnings report 10-Q filing, and delivers plain-English takeaways you can act on. Need to monitor CeriBell insider trading Form 4 transactions? We stream CeriBell Form 4 insider transactions real-time, alerting you the moment an executive buys or sells. Material news breaks? A fresh 8-K appears and we publish CeriBell 8-K material events explained within minutes.
The result is clarity. Use our AI to compare R&D spend trends, track device-unit placements, or probe management incentives inside the next CeriBell proxy statement executive compensation. Dive into a concise CeriBell earnings report filing analysis or ask a natural question such as �understanding CeriBell SEC documents with AI� and get answers fast. From risk-factor red-flags to CeriBell executive stock transactions Form 4, every insight lives here—updated in real time and explained simply. No more endless scrolling through EDGAR; confident decisions start now.
Ceribell, Inc. (Nasdaq: CBLL) submitted a Form 8-K to disclose a material legal development dated 7 July 2025. The filing states that the company has filed complaints with both the U.S. International Trade Commission and the U.S. District Court for the District of Delaware against Natus Medical Incorporated and certain subsidiaries. Ceribell alleges that Natus is infringing six Ceribell patents covering key elements of the Ceribell EEG headband and electrode design and is engaging in unfair competition. A copy of the related press release is included as Exhibit 99.1 and incorporated by reference. No financial statements, guidance, or earnings metrics are provided in this report.
The 8-K limits its disclosure to the existence of the complaints, the forums in which they were filed, and the patents� connection to “important features� of the company’s EEG technology. No information is given regarding potential damages sought, litigation timetable, or expected financial impact. The report contains no other business updates under Item 8.01 and lists only the press release and cover-page XBRL file under Item 9.01.
Form 144 filing for CeriBell, Inc. (symbol: CBLL) discloses that an affiliate, Xingjuan Chao, plans to sell up to 25,000 common shares through Fidelity Brokerage Services. The proposed sale, valued at $470,000, represents roughly 0.07 % of the 36.14 million shares outstanding and is expected to occur on or about 07 July 2025 on the NASDAQ exchange.
The shares stem from an employee option granted on 07 July 2021 and exercised for cash on the same date as the planned sale. During the previous three months, the same seller executed six separate transactions totaling 75,000 shares and generating � $1.23 million in gross proceeds.
No additional financial statements, earnings figures, or corporate actions are included in this filing. The document is limited to the proposed share sale details required under SEC Rule 144.
Armada Hoffler Properties (AHH) Form 4: Director Dennis H. Gartman received 7,938 restricted common shares on 06/18/2025 at a stated price of $0.
The award will vest in full at the 2026 Annual Meeting, increasing his direct holding to 44,603 shares. This is routine board compensation with negligible dilution and no cash impact, intended to align the director’s interests with shareholders rather than signal a change in sentiment or fundamentals.
Lifeward Ltd. (Nasdaq: LFWD) has filed a Rule 424(b)(4) prospectus for a combined ordinary-share/warrant offering designed to raise up to $2.6 million in gross proceeds. The company will sell 4,000,000 ordinary shares at $0.65 per share and issue an equal number of five-year warrants with an identical $0.65 exercise price. H.C. Wainwright & Co. is acting as exclusive placement agent on a reasonable-best-efforts basis; consequently, there is no minimum capital raise or escrow, and funds will be made immediately available to Lifeward.
Capital structure impact. Shares outstanding will rise from 11.6 million to 15.6 million (34% dilution) before any warrant exercises. The placement agent will also receive 240,000 five-year warrants exercisable at $0.8125. Lifeward already has approximately 4.3 million legacy warrants outstanding (exercise prices $2.75-$52.50) and 0.3 million equity awards reserved, so potential fully-diluted share count materially exceeds current levels.
Use of proceeds. After 7% placement fee, 1% management fee and ~$165k estimated expenses, net proceeds are projected at roughly $2.0 million. Management intends to allocate funds to ongoing commercial efforts (including AlterG integration, exoskeleton penetration via CorLife, and geographic expansion), working capital and general corporate purposes. Given a Q1-25 accumulated deficit of $269.7 million and a going-concern warning, the raise provides only short-term liquidity.
Security terms. � Warrants are immediately exercisable, expire five years from the initial exercise date and contain a 4.99%/9.99% ownership blocker. � No public market is expected for the warrants, limiting liquidity. � Fundamental-transaction language grants cash or “Black-Scholes value� redemption rights on change-of-control events.
� Company and insiders are subject to a 60-day lock-up.
Strategic context. Lifeward is a medical-device firm focused on exoskeleton and rehabilitation technologies (ReWalk, ReStore, AlterG). Recent milestones include FDA clearance for stair functionality, submission of ReWalk 7, and the AlterG acquisition. Nonetheless, a challenging reimbursement environment, paused ReBoot development and the need for additional capital underscore execution risk.
Key investor considerations:
- Limited runway: $2 million net proceeds vs. ongoing losses raise probability of further dilution or debt.
- Highly dilutive structure: potential 8.2 million new shares from this transaction (shares + warrants + PA warrants).
- Going-concern disclosure: auditor’s opinion and management statements highlight liquidity risk.
- Upside optionality: low exercise price warrants could double proceeds if future share price exceeds $0.65.
- Pipeline progress: FDA submissions, workers� compensation channel agreement and AlterG integration provide growth catalysts if adequately funded.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
What is the primary focus of CeriBell, Inc.?
How does the Ceribell System work?
What clinical settings utilize CeriBell's technology?
What regulatory approvals has the Ceribell System received?
How does CeriBell’s technology benefit patient care?
How does CeriBell differentiate itself from traditional EEG systems?
